MetaVia to Present at the Emerging Growth Conference in December
MetaVia to Present at the Emerging Growth Conference in December
CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company update at the Emerging Growth Conference on Wednesday, December 4, 2024 at 4:10 pm ET.
馬薩諸塞州劍橋，2024年12月2日，美妥威亞公司（納斯達克股票代碼：MTVA），一家專注於轉化心臟代謝疾病的臨床生物技術公司，今日宣佈，總裁及首席執行官金亨賢（Hyung Heon Kim）和首席財務官馬歇爾·伍德沃斯（Marshall H. Woodworth）將於2024年12月4日星期三下午4:10在新興增長大會上進行公司更新報告。
After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to [email protected], or ask your questions during the event.
在報告結束後，美妥威亞管理層將開放提問環節。請提前將您的問題提交至[email protected]，或在活動期間提問。
Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at [email protected].
請使用此鏈接註冊參加虛擬大會並接收發布的任何更新。若要安排在大會之外與管理層會面，請聯繫邁克爾·米勒（Michael Miller）[email protected]。
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
關於美妥威亞
美妥威亞公司是一家專注於轉化心臟代謝疾病的臨床生物技術公司。該公司目前正在開發DA-1726用於肥胖症的治療，並正在開發DA-1241用於治療代謝紊亂相關脂肪肝（MASH）。DA-1726是一種新型的氧唑調質素（OXM）類似物，作爲胰高血糖素樣肽-1受體（GLP1R）和胰高血糖素受體（GCGR）雙激動劑發揮作用。OXM是一種自然存在的腸道激素，可激活GLP1R和GCGR，從而減少食物攝入，增加能量消耗，因此可能導致比選擇性GLP1R激動劑更優越的體重減輕效果。DA-1241是一種新型的G蛋白偶聯受體119（GPR119）激動劑，促進關鍵胃腸肽GLP-1、GIP和PYY的釋放。在臨床前研究中，DA-1241對肝臟炎症、脂肪代謝、體重和葡萄糖代謝產生了積極影響，減少了肝臟脂肪變性、肝臟炎症和肝纖維化，同時改善了葡萄糖控制。
For more information, please visit .
更多資訊，請訪問。
Contacts:
聯繫人：
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
[email protected]
美妥威亞
Marshall H. Woodworth
首席財務官
+1-857-299-1033
[email protected]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
SOURCE MetaVia Inc.
源自MetaVia公司。